Showing 4451-4460 of 7638 results for "".
- Phase 3 Results Promising for Oral Psoriasis Agenthttps://practicaldermatology.com/news/20140422-phase_3_results_promising_for_oral_psoriasis_agent/2459260/Results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program indicate that the investigational oral Janus kinase (JAK) inhibitor tofacitinib (Pfizer) is both safe and effective for patients with moderate to severe psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 st…
- Dermatologist Launches Kickstarter Campaignhttps://practicaldermatology.com/news/20140422-dermatologist_launches_kickstarter_campaign/2459261/Steven Feldman, MD, PhD, is spearheading a new Kickstarter campaign entitled “Changes in the Landscape” for the Coalition for Peace and Justice, an organization that welcomes all individuals and groups working for a just and sustainable peace in Israel-Palestine. The goal of the campaign is to cre…
- Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lineshttps://practicaldermatology.com/news/20140421-revance_therapeutics_announces_positive_results_from_the_rt002_phase_12_study_in_glabellar_frown_lines/2459262/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorp…
- La Roche-Posay's "Dermatologist from the Heart" Accepting Applicationshttps://practicaldermatology.com/news/20140421-la_roche-posays_dermatologist_from_the_heart_accepting_applications/2459264/La Roche-Posay is accepting grant application for its “Dermatologist from the Heart” program in the United States. Now in its second year in the US, “Dermatologist from the Heart” aims to support initiatives designed to enhance the quality of life for patients. Through this program, the La Fondat…
- Innocutis Introduces Dexter the Dystrophic Nail to Educate Patientshttps://practicaldermatology.com/news/20140417-innocutis_introduces_dexter_the_dystrophic_nail_to_educate_patients/2459265/Innocutis launched an animated social media campaign to educate on the prevalence of nail dystrophy and Nuvail as a viable treatment option. The antagonist of healthy nails in what the company calls a “fun, light-hearted, social media campaign” is Dexter, the dystrophic nail. Dexter epitomizes nail…
- Dermatology Resident Survey Finds Practice Gaps in Patient Safetyhttps://practicaldermatology.com/news/20140417-dermatology_resident_survey_finds_practice_gaps_in_patient_safety/2459267/A 2012 survey-based study of 142 dermatology residents from 44 US and Canadian residency programs was conducted to identify the source of clinical practices among dermatology residents that affect patient safety and determine the best approach for overcoming gaps in knowledge and practice patterns …
- bioskin Continues US Expansion with Launch of New Websitehttps://practicaldermatology.com/news/20140417-bioskin_continues_us_expansion_with_launch_of_new_website/2459268/bioskin® follows expansion of its US office, spearheaded by AJ Acker, Executive Director of Global Regulatory and Clinical Affairs, with the launch of our a website www.bioskinCRO.com. The new layout was designed with ease of use in mind and highlighting our areas of dermatological expertise includ…
- SkinCeuticals Announces the Launch of its First US Flagship Locationhttps://practicaldermatology.com/news/20140414-skinceuticals_announces_the_launch_of_its_first_us_flagship_location/2459274/SkinCeuticals launched SkinCeuticals Advanced Clinical Spa with Manhattan Dermatology and Cosmetic Surgery, the first flagship location. An exclusive Integrated Skincare treatment menu has been created, featuring comprehensive offerings that range from clinical procedures to SkinCeuticals advanced …
- TetraLogic Acquires Shape Pharmaceuticals, Inc.https://practicaldermatology.com/news/20140407-tetralogic_acquires_shape_pharmaceuticals_inc/2459275/TetraLogic Pharmaceuticals Corporation has entered an agreement to acquire Shape Pharmaceuticals, a biotechnology company. Shape Pharmaceuticals is developing SHAPE, which is a tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma. J. Kevin Bu…
- Sun Pharma Acquires Ranbaxy in a $4 billion US Transactionhttps://practicaldermatology.com/news/20140407-sun_pharma_acquires_ranbaxy_in_a_4_billion_us__transaction/2459276/Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction. The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents. Managing Directo…